CATB Catabasis Pharmaceuticals Inc.

6.03
-0.48  -7%
Previous Close 6.51
Open 6.51
Price To Book 1.86
Market Cap 71,137,068
Shares 11,797,192
Volume 211,541
Short Ratio
Av. Daily Volume 115,955
Stock charts supplied by TradingView

NewsSee all news

  1. Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial

    -- Duchenne UK Grants Over $600,000 in Funding to Support Patient and Clinical Trial Site Costs -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity

  2. Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population

    -- Analysis Shows Patients Enrolled in Phase 2 MoveDMD and Phase 3 PolarisDMD Trials of Edasalonexent in Duchenne Muscular Dystrophy Have Similar Baseline Characteristics -- Catabasis Pharmaceuticals, Inc.

  3. Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress

    -- Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020 -- -- Conference Call and Webcast Today at 8:30am ET -- Catabasis

  4. Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019. Jill C.

  5. Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 4Q 2020.
Edasalonexent (CAT-1004)
Duchenne muscular dystrophy (DMD)
Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia

Latest News

  1. Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial

    -- Duchenne UK Grants Over $600,000 in Funding to Support Patient and Clinical Trial Site Costs -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity

  2. Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population

    -- Analysis Shows Patients Enrolled in Phase 2 MoveDMD and Phase 3 PolarisDMD Trials of Edasalonexent in Duchenne Muscular Dystrophy Have Similar Baseline Characteristics -- Catabasis Pharmaceuticals, Inc.

  3. Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress

    -- Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020 -- -- Conference Call and Webcast Today at 8:30am ET -- Catabasis

  4. Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019. Jill C.

  5. Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by

  6. Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

    -- Differentiating Safety and Tolerability Profile of Edasalonexent Through More Than 55 Patient Years of Exposure -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today

  7. Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

    -- Top-line Results Expected Fourth Quarter of 2020 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD

  8. Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular

  9. Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

    -- Edasalonexent Inhibits NF-kB, a Potential Driver of Disease Progression in Dysferlinopathy -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and the Jain Foundation, a

  10. Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer. Mr. Komjathy brings to Catabasis more than 30